Abstract
Purpose
Denosumab is approved for the prevention of skeletal-related events (SREs) in metastatic solid tumor patients with bone metastases. Limited data regarding the safety of denosumab in patients with severe renal insufficiency suggests increased rates of hypocalcemia compared to patients with normal renal function. The purpose of this study was to assess the rates of hypocalcemia and hypophosphatemia in cancer patients with severe renal impairment.
Methods
In this case series, patient demographics, primary tumor site, number of denosumab doses, and episodes of hypocalcemia and hypophosphatemia were retrospectively obtained by patient chart review. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft-Gault equation. Twenty-two metastatic solid tumor patients with severe renal insufficiency (creatinine clearance <30 mL/min) who had received denosumab at a dose of 120 mg were included.
Results
Ten of 22 patients (45 %) experienced a hypocalcemic event of any grade. Three patients (14 %) had grade 3 hypocalcemia, and no patients had grade 4 hypocalcemia. The median number of doses of denosumab prior to calcium nadir was one. Seven of 22 patients (32 %) experienced hypophosphatemia of any grade including grade 3 events in two patients (9 %).
Conclusions
Denosumab resulted in increased rates of hypocalcemia when administered to metastatic solid tumor patients with severe renal impairment for the prevention of SREs compared to previously reported rates of hypocalcemia in the general population. However, all cases of hypocalcemia were asymptomatic and resolved prior to subsequent dosing. Due to a higher rate of hypocalcemia than reported in patients with normal renal function, patients with severe renal impairment should receive close monitoring of calcium levels while receiving denosumab.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588–1594
Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19(1):80
Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420
Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677–692
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28(35):5132
Fizazi K, Carducci M, Smith M, Damião R, Brown J et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813
Pamidronate (Aredia®). East Hanover, New Jersey: Novartis Pharmaceuticals. 2012
Zoledronic acid (Zometa®). East Hanover, New Jersey: Novartis Pharmaceuticals. 2012
Denosumab (Xgeva®). Thousand Oaks, California: Amgen. 2013
Block G, Bone HG, Fang L, Lee E, Padhi D (2012) A single dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 27(7):1471–1479
Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR et al (2011) Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 26(8):1829–1835
Denosumab (Prolia®). Thousand Oaks, California: Amgen. 2014
Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF (2013) Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med 31(4):756.e1–756.e2
Govaerts E, Vansteenkiste J (2013) Use of denosumab in a patient with non-small-cell lung cancer and severe renal function impairment. J Thorac Oncol 8(6):e52–e53
Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S (2014) Severe hypocalcemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol 2014:565393. doi:10.1155/2014/565393
Okada N, Kawazoe K, Teraoka K, Kujime T, Abe M et al (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biol Pharm Bull 36(10):1622–1626
Lechner B, DeAngelis C, Jamal N, Emmenegger U, Pulenzas N et al (2014) The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. Support Care Cancer 22(7):1765–1771
Lee JW (2010) Fluid and electrolyte disturbances in critically ill patients. Electrolyte Blood Press 8(2):72–81
Qi WX, Lin F, He AN, Tang LN, Shen Z, Yao Y (2013) Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin 29(9):1067–1073
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE et al (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9):1221–1227
Conflict of interest
Financial disclosures: None of the authors have any relevant financial or commercial interest to disclose.
Support: No financial support was received for this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Watkins, K.R., Rogers, J.E. & Atkinson, B. Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency. Support Care Cancer 23, 1657–1662 (2015). https://doi.org/10.1007/s00520-014-2521-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2521-8